「Debut Biotechnology」宣布公司在B轮融资中获得3400万美元融资，以用于业务范围的扩大。该轮融资由BOLD领投，Fine Structure Ventures、Material Impact、GS Futures、Cavallo Ventures、Cultivian Sandbox Ventures、ACVC Partners等参与。 据悉，Debut Biotechnolog ...

引言免疫治疗最令人着迷的地方，是它并不直接“毒杀”癌细胞，而是试图让免疫系统重新看见肿瘤。但问题也恰在这里：很多肿瘤并非没有抗原，而是把周围微环境改造成了一个免疫低反应区。T细胞进不来，树突状细胞不成熟，抗原呈递不足，检查点抑制剂也常常缺少“可释放的 ...

引言如果一个基因编辑工具在试管里很强，却在细胞里“站不稳”，它还能走向治疗吗？这正是5月21日发表于 《Nature Biotechnology》 的研究 “AI-guided redesign of laboratory-evolved ...

Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent filings.

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

Vir Biotechnology has a cash runway into 2028 and pivotal 2026 catalysts for its lead hepatitis drugs. Learn why VIR stock is a buy.

Masinde Muliro University of Science and Technology and National Biosafety Authority signs MoU to train students on biotechnology related courses /HANDOUTNationalBiosafety Authority has signed a ...

Department of Biotechnology has extended the application deadline for the DBT-Research Associateship 2025–26 to May 27. The postdoctoral fellowship supports advanced research in Biotechnology and Life ...